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Background: There is a relationship among hypercholesterolemia, oxidative stress and inflammation in the
atherogenesis. Thus, the objective of the present study was to assess paraoxonase (PON1), superoxide dismutase
(SOD) and thioredoxin reductase (TrxR-1) activities and their relationship with lipids, oxidative stress and
inflammation in subjects with different low density lipoprotein-cholesterol (LDL) levels.
Methods: Serum lipids, highly sensitive C-reactive protein (hs-CRP), lipid and protein oxidation, oxidized LDL
(LDLox) and LDLox autoantibodies (LDLoxAB) levels and enzymes activities were measured in a total of 116
subjects that were divided into the following groups according to their LDL levels: low-LDL group (LDL < 100 mg/dL,
n = 23), intermediate-LDL group (LDL 100–160 mg/dL, n = 50) and high-LDL group (LDL > 160 mg/dL, n = 43).
Results: The LDLox and hs-CRP levels increased in the high-LDL group (2.7- and 3.7- fold, respectively), whereas the
intermediate and high-LDL groups had higher LDLoxAB (2.2- and 3.1-fold) when compared to low-LDL group
(p < 0.05). Similarly, SOD activity, the atherogenic index (AI) and protein oxidation were also higher in the
intermediate (1.3-, 1.3- and 1.2-fold) and high-LDL (1.6-, 2.3- and 1.6-fold) groups when compared to the low-LDL
group (p < 0.05). Lipid oxidation and SOD/TrxR-1 ratio increased only in the high-LDL group (1.3- and 1.6-fold) when
compared to the low-LDL group (p < 0.05). The SOD/TrxR-1 ratio was positively correlated to TBARS (r = 0.23,
p < 0.05), LDLox (r = 0.18, p < 0.05), LDLoxAB (r = 0.21, p < 0.05), LDL (r = 0.19, p < 0.05) and AI (r = 0.22, p < 0.05). PON1
and TrxR-1 activities were similar among groups.
Conclusions: Some oxidative events initiate when LDL levels are clinically acceptable. Moreover,
hypercholesterolemic patients have an imbalance in SOD and TrxR-1 activities that is positively associated
to LDL oxidation.
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Table 1 Characteristics of the studied groups
Groups (LDL-cholesterol levels)
Low-LDL Intermediate-LDL High-LDL
(< 100 mg/dL) (100–160 mg/dL) (> 160 mg/dL)
N 23 50 43
Sex (male/female) 12/11 26/24 16/27
Age (years) 55.9+2.3 54.1+1.9 55.3+1.5
(34.0-77.0) (29.0-87.0) (31.0-75.0)
TC (mg/dL) 143.9+5.4c 212.1+3.5b 274.4+6.1a
(84.0-188.0) (138.0-270.0) (226.0-449.0)
TG (mg/dL) 104.3+13.8b 143.9+13.1a 149.8+8.8a
(20.0-317.0) (32.0-430.0) (67.0-300.0)
LDL (mg/dL) 81.3+3.6c 134.9+2.2b 202.9+5.8a
(33.8-99.6) (102.4-159.0) (162.0-341.8)
HDL (mg/dL) 41.0+2.4b 48.5+1.9a 41.5+1.9b
(23.0-72.0) (21.0-95.0) (20.0-91.0)
AI 2.7+0.2c 3.6+0.2b 6.1+0.4a
(1.5-5.5) (1.6-5.8) (2.2-19.3)
Results are expressed as mean + SEM (minimum – maximum).
a,b,c Values within the same line that do not share a common superscript letter
are significantly different from each other (p < 0.05). TC = total cholesterol;
TG = triglycerides; LDL = low-density lipoprotein; HDL = high-density
lipoprotein; AI = atherogenic index.
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Atherosclerosis is the main underlying mechanism of
leading causes of death, such as heart and brain disor-
ders [1]. Hypercholesterolemia (HC), especially high
levels of low density lipoprotein-cholesterol (LDL),
seems to be an important risk factor accounting for se-
vere atherosclerotic diseases, since LDL enters into the
vessel walls by a concentration-dependent mechanism.
Once into the endothelium, LDL suffers oxidative attack
by reactive oxygen species (ROS) on its lipid and protein
components, generating oxidized LDL (LDLox) [2]. Add-
itionally, LDLox can initiate and enhance the inflamma-
tory process, which plays a pivotal role in the
development of atherosclerotic changes [3]. Accordingly,
the level of highly sensitive C-reactive protein (hs-CRP),
an inflammatory marker, is enhanced in patients with
high levels of total cholesterol [3].
It has been suggested that high density lipoprotein
(HDL) protects LDL particles from the oxidative process
and subsequent inflammation [4]. This protective action
of HDL is due to its associated enzyme paraoxonase 1
(PON1) [4]. Although PON1 activity is inversely asso-
ciated to the incidence of coronary artery disease [5],
there is no data on the behavior of PON1 during differ-
ent stages of HC.
Since superoxide anion is thought to be one of the
most important reactive oxygen species in the patho-
genesis of atherosclerotic coronary artery diseases [6],
extracellular superoxide dismutase (EC-SOD) plays a
central role in cardiovascular antioxidant mechanisms.
This SOD isoenzyme is mainly synthesized and
secreted from vascular smooth muscle cells and
macrophages and is the predominant arterial SOD iso-
form [7]. Thioredoxin reductase (TrxR-1) is a redox-
active selenoprotein that efficiently regenerates oxidized
thioredoxin protein (Trx-1) to its reduced form [8].
Reduced Trx-1 has an antioxidant function because it
maintains the reduced state of many proteins [8]. Fur-
thermore, TrxR-1 is overexpressed and released during
oxidative stress and has been detected in plasma [9].
Although elevated Trx-1 levels have been found during
HC and heart failure in humans [10,11], few reports
are available on the behavior of TrxR-1 during coron-
ary events or in patients with major risk factors, such
as HC [12,13].
Considering the link among HC, oxidative stress
and inflammation in the atherogenesis, this study
reported the behavior of PON1 activity, as well as, the
antioxidants SOD and TrxR-1 activities in the differ-
ent stages of HC development. We also investigated
the associations among the activity of these enzymes,
oxidative stress and inflammatory markers and circu-
lating lipids in the blood of subjects with different
LDL levels.Results
Population characteristics are shown in Table 1. No sig-
nificant difference was found among groups concerning
age (p > 0.05). Total cholesterol (TC) levels increased sig-
nificantly along with the increase in LDL levels among
groups (p < 0.05). Triglycerides (TG) levels were also
higher in the intermediate- and high-LDL groups when
compared to the low-LDL group (p < 0.05), but no dif-
ference was observed between the high- and
intermediate-LDL groups. In contrast, intermediate-
LDL group had higher HDL levels than the other
groups (p < 0.05). In addition, the atherogenic index
(AI) increased in groups along with the increase in LDL
levels (p < 0.05, Table 1).
One-way ANOVA revealed that patients from the
high-LDL group showed significantly increased thiobar-
bituric acid reactive substances (TBARS) levels when
compared to the low- and intermediate-LDL groups
(p < 0.05, Table 2). On the other hand, protein carbonyl
content increased in the intermediate- and high-LDL
groups when compared to the low-LDL group (p < 0.05,
Table 2), but no significant differences were found be-
tween the intermediate- and high-LDL groups. LDL
levels affected LDLox and the levels of the inflammatory
marker hs-CRP in the same way of TBARS levels, as it
can be revealed by the nonparametric Kruskal-Wallis
test (p < 0.05, Table 2). The LDLox autoantibodies
(LDLoxAB) levels of patients from the intermediate- and
Table 2 Oxidative stress and inflammatory markers in patients with different LDL levels
Groups (LDL-cholesterol levels)
Low-LDL Intermediate-LDL High-LDL
(<100 mg/dL) (100–160 mg/dL) (>160 mg/dL)
TBARS (nmol MDA/mL) 4.9+0.3b 5.1+0.2b 6.3+0.3a
(2.5-8.5) (2.4-8.0) (4.0-13.3)
Protein carbonyl content 1.2+0.1b 1.4+0.1a 1.9+0.2a
(nmol/mg of protein) (0.2-2.9) (0.7-4.9) (0.5-6.7)
LDLox (mg/L) 0.27+0.06b 0.39+0.04b 0.73+0.06a
(0.0-1.0) (0.0-1.7) (0.03-1.9)
LDLoxAB (mg/L) 10.3+2.1c 22.4+1.5b 32.1+1.4a
(0.7-36.0) (0.8-46.4) (9.2-54.7)
hs-CRP (mg/L) 0.42+0.07b 0.81+0.16b 1.55+0.26a
(0.1-1.2) (0.1-7.9) (0.1-7.9)
Results are expressed as mean + SEM (minimum – maximum). N = 23–50, as shown in Table 1. a,b,c Values within the same line that do not share a common
superscript letter are significantly different from each other (p < 0.05). TBARS = thiobarbituric acid reactive substances; MDA = malondialdehyde; LDLox = oxidized
LDL; LDLoxAB = LDLox autoantibodies; hs-CRP = highly sensitive C-reactive protein.
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from the low-LDL group (p < 0.05, Table 2).
SOD activity was significantly higher in patients from
the intermediate- and high-LDL groups compared to the
low-LDL group (p < 0.05) and significant differences were
found between the intermediate and high-LDL groups
(Figure 1A). No significant differences were observed in
TrxR-1 or PON1 activities among groups (p > 0.05,
Figure 1B and 1C). Because TrxR-1 could be important to
reduce the hydrogen peroxide (H2O2) that is generated
during the dismutation of superoxide anion radical by
SOD, we have also assessed the SOD/TrxR-1 ratio to
verify a possible imbalance between these activities. The
SOD/TrxR-1 ratio increased in the high-LDL group
when compared to the low-LDL group, but no difference
was observed between the low- and intermediate-LDL
groups or between the intermediate- and high-LDL
groups (p < 0.05, Figure 1D).
LDL levels were positively correlated to TC, TG,
TBARS levels, protein carbonyl content, LDLox,
LDLoxAB and hs-CRP levels as well as to AI, SOD activ-
ity and SOD/TrxR-1 ratio (p < 0.05, Table 3). In contrast,
LDL levels had no significant correlation with HDL
levels, TrxR-1 or PON1 activities (p > 0.05, Table 3). A
positive correlation was observed between TrxR-1and
SOD activities (p < 0.05, Table 3). Despite the lack of add-
itional associations of TrxR-1 with oxidative or inflam-
matory markers, SOD/TrxR-1 ratio was positively
correlated with TBARS, LDLox and LDLoxAB levels, as
well as, with the AI (p < 0.05, Table 3). Hs-CRP levels
were positively correlated with LDLox as well as with
LDLoxAB levels (p < 0.05, Figure 2A and 2B). In addition,
we also found a positive correlation between TBARS and
LDLox levels (p < 0.05, Figure 2C). PON1 activity had nocorrelation with oxidative or inflammatory markers in
the present study (p > 0.05, Table 3).
Discussion
Elevated plasma cholesterol levels play a dominant role
in cardiovascular diseases [1] as can be evidenced by the
occurrence of atheroma in the aorta of hypercholestero-
lemic rabbits [14]. Accordingly, the AI, which reflects
the relationship between the non-HDL cholesterol frac-
tion and the HDL cholesterol fraction and is considered
a possible indicator of a predisposition to heart disease
[15], was directly correlated to the increase in LDL
levels. The injury theory of atherosclerosis holds that cir-
culating LDL accumulates at susceptible sites where the
oxidation of its protein and lipid components takes
place, generating LDLox [2]. LDLox, in turn, participates
in the inflammatory processes, contributing to lesion
progression [3]. Our results corroborate this theory,
since elevated LDLox levels were found in patients from
the high-LDL group. Accordingly, lipid oxidation
(TBARS) was also increased in patients from the high-
LDL group and we observed a positive correlation be-
tween TBARS and LDLox, reinforcing that TBARS levels
are at least partially associated to LDLox levels. In con-
trast to lipid oxidation, protein oxidation seems to start
even when LDL levels are considered clinically accept-
able, because the protein carbonyl content was increased
in the intermediate-LDL group. The delay in the in-
crease of LDL oxidation in the intermediate-LDL group
may be related to a protective effect of LDLoxAB that
was increased in this group compared to the low-LDL
group. This idea is supported by previous studies which
demonstrated that even minor modifications of native
LDL render it immunogenic and that humoral
Figure 1 SOD (A), TrxR-1 (B) and PON1 (C) activities and SOD/TrxR-1 ratio (D) of patients with different LDL levels. Results are expressed
as mean + SEM (n = 23–50, as shown in Table 1). *Significantly different from the low-LDL group (p < 0.05). SOD = superoxide dismutase;
TrxR-1 = thioredoxin reductase 1; PON1 = Paraoxonase 1.
Table 3 Associations among lipid levels, oxidative stress
and inflammatory markers
Parameters Correlation coefficients (R)
LDL PON1 TrxR-1 SOD/TrxR-1
TC (mg/dL) 0.92* −0.03 0.12 0.15
HDL (mg/dL) −0.11 0.10 0.04 −0.09
TG (mg/dL) 0.21* −0.09 0.002 0.06
Hs-CRP (mg/L) 0.46* −0.06 −0.03 0.11
Protein carbonyl
(nmol/mg of protein)
0.27* 0.05 0.08 0,00
TBARS (nmol MDA/mL) 0.33* 0.06 −0.05 0.23*
LDLox (mg/L) 0.49* −0.02 −0.11 0.18*
LDLoxAB (mg/L) 0.66* −0.04 −0.04 0.21*
AI 0.74* −0.09 0.05 0.19*
SOD (U/L) 0.41* −0.06 0.18* -
TrxR- 1 (U/L) 0.10 0.05 - -
SOD/TrxR-1 0.19* −0.06 - -
PON1 (U/mL) −0.03 - - -
TC = total cholesterol; TG = triglycerides; TBARS = thiobarbituric acid reactive
substances; MDA = malondialdehyde; SOD = superoxide dismutase;
TrxR-1 = thioredoxin reductase 1; PON1 = Paraoxonase 1; LDLox = oxidized
LDL; LDLoxAB = LDLox autoantibodies; hs-CRP = highly sensitive C-reactive
protein; AI = atherogenic index.
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[16,17]. These findings indicate that circulating anti-
bodies respond to oxidative modifications in the protein
moiety of LDL. In addition, humoral antibodies to modi-
fied LDL may redirect its site of degradation, primarily
from plasma to the reticuloendothelial cells of the liver
from rabbits [18]. Thus, LDLoxAB could enhance the
removal of LDLox from serum and prevent its entrance
into the arterial wall. In agreement, an inverse relation-
ship between LDLoxAB and LDLox levels in healthy
subjects is in line with the idea that LDLoxAB has a role
in the clearance of LDLox from the circulation [19].
Moreover, at low rates of LDL oxidation, it is possible
that an immune response might lead to an accelerated
macrophage uptake of LDLox and thereby it may play a
protective role. When the rate of oxidation is enhanced,
however, the immune response might play a pathogen-
etic role, leading to accelerated macrophage uptake
that overwhelms the capacity of the macrophage to
handle the ingested LDLox [20]. Thus, we can specu-
late that the rate of oxidation in the intermediate-LDL
group is low and LDLoxAB are still able to counteract
LDLox, whereas in the high-LDL group this protection
did not occur.
Figure 2 Significant correlations between hs-CRP and LDLox (A), hs-CRP and LDLoxAB (B) and TBARS and LDLox (C). TBARS =
thiobarbituric acid reactive substances; MDA = malondialdehyde; LDLox = oxidized LDL; LDLoxAB = LDLox autoantibodies; hs-CRP = highly
sensitive C-reactive protein.
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levels among groups and this increase occurred most
likely to counteract the superoxide anion overproduction
caused by HC [21]. The increase in SOD activity, along
with the increase in protein carbonyl and LDLoxAB
levels, even when LDL levels are considered clinically ac-
ceptable; indicate that oxidative stress is an early event
in the evolution of hyperlipidemia.
The enzyme TrxR-1 along with protein Trx-1 has been
recognized as an essential component for cellular redox
control and antioxidant defense [8]. In this study, we
demonstrated for the first time the behavior of serum
TrxR-1 activity during different stages of HC in humans,
although an elevation in serum reduced Trx-1 has
already been described in patients with HC [10]. Add-
itionally, we have recently demonstrated an increase in
serum TrxR-1 activity in hypercholesterolemic rabbits
[22]. However, in the present study, we observed no sta-
tistically significant differences in TrxR-1 activity amonggroups. The thioredoxin system (TrxR-1 and Trx-1) acts
as a H2O2 scavenging system, reducing H2O2 to H2O
[8]. Besides scavenging H2O2, TrxR-1 can indirectly
maintain the reduced state of many proteins by regener-
ating oxidized Trx-1 to its reduced form [8]. Thus, we
can speculate that the lack of changes in TrxR-1 activity
in the intermediate-LDL group resulted in the increase
of protein oxidation in this group. However, no associ-
ation was found between TrxR-1 activity and protein
carbonyl levels. Despite the unchanged activity of TrxR-
1 among groups, we found a weak, but significant cor-
relation between TrxR-1 and SOD activities, which
could indicate a role for TrxR-1 in the removal of H2O2
produced by SOD. Interestingly, in the high-LDL group,
SOD activity had a prominent increase over TrxR-1 ac-
tivity, as measured by the increased SOD/TrxR-1 ratio.
This imbalance in SOD/TrxR-1 activities suggests that
TrxR1 activity could be lacking to efficiently remove the
H2O2 produced by SOD. Because the SOD/TrxR-1 ratio
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LDLoxAB levels, we can speculate that the imbalance in
SOD/TrxR1 ratio could have deleterious effects in
hypercholesterolemic subjects due to a peroxide over-
load. However, this proposal deserves further investiga-
tion because glutathione peroxidase and catalase, which
are other important enzymes to remove H2O2 in plasma,
were not evaluated in the present study. In fact, an im-
balance between SOD and catalase activities has been
well documented in various oxidative conditions [23,24],
but to the best of our knowledge, this is the first report
about an imbalance between SOD and TrxR-1 activity.
Because the SOD/TrxR-1 ratio was associated with the
AI, we can suggest a possible role of the SOD/TrxR-1
ratio as a marker of cardiovascular events during HC.
Similar to TrxR-1, the behavior of PON1 activity at
different stages of HC has not been demonstrated yet.
PON1 is believed to be responsible for the antioxidant
effects of HDL [4] and its activity is inversely associated
with the progression of atherosclerosis and the incidence
of coronary artery disease [5]. In agreement, previous
results from our group revealed diminished serum
PON1 activity along with atherosclerotic plaque in the
aorta of hypercholesterolemic rabbits [22]. Moreover, a
large prospective study pointed low serum PON1 activity
as an independent risk factor for coronary events in men
at high risk of coronary heart disease [25]. However, we
did not found differences in PON1 activity among the
three studied groups or significant correlations between
LDL levels and PON1 activity. This could be explained
by an established balance between PON1 inactivation by
oxidant species [26] and PON1 elevation in order to
provide a protective mechanism against oxidant species
and atherosclerotic plaque progression [27]. These dif-
ferences in PON1 activity between previous studies and
ours can be due the fact that studies concerning PON1
and cardiovascular diseases usually evaluated the rela-
tionship between serum enzyme activity and plaque for-
mation [28] or cardiovascular events such as myocardial
infarction [25]. Here, we evaluated the relationship be-
tween PON1 activity and another known predicting fac-
tor for cardiovascular diseases, the LDL levels.
Moreover, PON1 seems not play a role in early athero-
sclerosis, although it may play a role in a later stage of
cardiovascular diseases [29]. Since the atheroma forma-
tion was not evaluated in this study, we can speculate
that unchanged PON1 activity and the lack of associa-
tions between PON1, LDL and LDLox levels are most
likely because LDL levels evaluated in this study corre-
sponded to early stages of atherosclerosis.
The involvement of oxidative stress in the initiation
and progression of the inflammatory process is well
documented [3]. Accordingly, we observed a significant
correlation between LDLox and hs-CRP, which is aninflammatory marker. Moreover, serum hs-CRP levels
were increased in the high-LDL group. Despite the
changes in SOD and SOD/TrxR-1 ratio that accompan-
ied the increase in LDL levels, no relationship was found
between hs-CRP levels and antioxidant enzymes. This
lack of correlation has already been described in the
serum of patients with rheumatoid arthritis, although
both parameters had been changed by the disease [30].
Although the extracellular reduced Trx-1 has proinflam-
matory effects by potentiating cytokine release from
fibroblasts and monocytes [8], our results reveal that
TrxR-1 seems to have no relationship with the inflam-
matory response during HC.
In conclusion, the present study demonstrated that
some oxidative events initiate even when LDL levels are
clinically acceptable. Moreover, hypercholesterolemic
patients show an imbalance in SOD/TrxR-1 activities,
which may play a role in the oxidative stress, because it
is positively associated to LDL oxidation.
Methods
Study population
The population studied consisted of patients from
LABIMED (Santa Maria, RS, Brazil). All subjects gave
written informed consent to participate in the study.
The work was carried out in accordance with The Code
of Ethics of the World Medical Association and the
protocol was approved by the Research Ethics Commit-
tee of the Federal University of Santa Maria (Protocol
number: 23081.019182/2007-10). Subjects were divided
into three groups according to the serum LDL levels, as
follows: low-LDL group comprised subjects with LDL
levels < 100 mg/dL (2.6 mmol/L); intermediate-LDL
group comprised subjects with LDL levels ranging from
100 to 160 mg/dL (2.6-4.15 mmol/L); and high-LDL
group comprised subjects with LDL levels > 160 mg/dL
(4.15 mmol/L). These LDL ranges were selected accord-
ing to the National Cholesterol Education Program [31],
where LDL levels < 100 mg/dL are considered safe; be-
tween 100 and 160 mg/dL are clinically acceptable, but
close to the limit; and LDL levels > 160 mg/dL are con-
sidered to be well above the safe limit for risk of cardio-
vascular diseases. Male and female subjects ageing 28 to
87 years-old were included in the study. Smokers, obese
and hypertensive patients as well as patients with infec-
tious diseases, metabolic syndrome and with blood glu-
cose levels > 95 mg/dL were excluded from the study.
Patients undergoing drug or vitamin treatment were also
excluded from the study.
Blood sample collection
Blood samples were collected after a 12-h overnight fasting
by venous puncture into VacutainerW (BD Diagnostics,
Plymouth, UK) tubes with no anticoagulant. Blood samples
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2500× g for 15 min, and aliquots of serum samples were
immediately used to assess TC, TG, HDL, LDLox,
LDLoxAB, hs-CRP, TBARS levels and TrxR-1 activity.
Then, serum samples were stored at −20°C for a maximum
of 4 weeks before remaining measurements.
Biochemical determinations
Lipid profile
TC and TG concentrations were measured by standard
enzymatic methods using Ortho-Clinical DiagnosticsW
reagents on a fully automated analyzer (Vitros 950W dry
chemistry system; Johnson & Johnson, Rochester, NY,
USA). HDL cholesterol was measured after precipitation
of apolipoprotein B-containing lipoproteins with dextran
sulfate and magnesium chloride, as previously described
[32]. LDL was estimated with the Friedewald equation
[33]. The AI was calculated as (TC - HDL cholesterol)/
HDL cholesterol as previously reported [34].
Oxidative stress markers
LDLox was determined by a capture ELISA according to
the manufacturer instructions (Mercodia AB, Uppsala,
Sweden) and as described before [35]. Serum samples
were added to microplate wells coated with high affinity
antibodies for LDLox. A peroxidase-conjugated antibody
and tetramethylbenzidine (TMB) as substrate for perox-
idase were used. The intensity of the yellow color, which
is directly proportional to the LDLox concentration, was
read at 450 nm. A standard curve was generated from
standard LDLox. LDLoxAB was determined using ELISA
as described by Wu and Lefvert [36]. Serum samples
were added to microplate wells coated with high affinity
antigen (LDLox). The methodology was similar to that
used to quantify LDLox and the intensity of the yellow
color that was directly proportional to the LDLoxAB
concentration was read at 450 nm. A standard curve
was generated from standard LDLoxAB. Lipid peroxida-
tion, measured as TBARS levels, was assessed after the
addition of 7.2 mM of butylated hydroxytoluene to pre-
vent further oxidation. The reaction with thiobarbituric
acid and extraction with n-butanol was performed as
previously described [37] and the reaction product was
determined at 535 nm using a standard curve of 1,1,3,3-
tetraethoxypropane. Protein oxidation was assessed as
protein carbonyl content based on the reaction of the
carbonyl groups with 2,4-dinitrophenylhydrazine to form
2,4-dinitrophenylhydrazone [38]. Samples were read at
370 nm and carbonyl content was calculated using the
molar absorption coefficient for aliphatic hydrazones
(22,000 M-1 cm-1). SOD activity was determined at
480 nm using 50 mM glycine buffer, pH 10.2, and 1 mM
epinephrine at 30°C [39]. SOD activity was expressed as
the amount of enzyme that inhibits the auto-oxidationof epinephrine to adrenochrome by 50%, which is equal
to 1 unit. TrxR-1 activity was determined using 5,5′-
dithiobis (2-nitrobenzoic acid) (DTNB) and reduced ad-
enine dinucleotide phosphate. The method is based on
the reduction of DTNB, which is indicated by an in-
crease in absorbance at 412 nm [40].
PON1 activity
PON1 activity was assessed by measuring the rate of
paraoxon hydrolysis to yield p-nitrophenol, at 412 nm
and 25°C [41]. The amount of p-nitrophenol generated
was calculated using the molar extinction coefficient
17,000 M-1 cm-1 and 1 U of PON1 activity is defined as
1 nmol of p-nitrophenol generated per minute [41].
Inflammation marker
Hs-CRP was measured by nephelometry according to
the manufacturer instructions (Dade Behring, Newark,
DE, USA).
Statistical analysis
Data were analyzed by one-way analysis of variance
(ANOVA) followed by unequal N HSD test when appro-
priate. Data that did not exhibit normal distribution
were transformed (log or square root transformation) in
order to meet ANOVA assumptions before analysis.
When a variable was found not following normal distri-
bution even after log or square root transformation, it
was analyzed by the nonparametric Kruskal-Wallis
ANOVA followed by the post hoc Dunn’s test when ap-
propriate. The associations between variables were eval-
uated by Pearson’s correlation for variables that had
normal distribution and by Spearman’s rank order cor-
relation for variables that did not exhibit normal dis-
tribution. Results were considered significant when
p < 0.05.
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